Based on its test results to date, the US Food and Drug Administration 1 November again refrained from calling for consumers and patients to stop taking ranitidine products due to concerns about nitrosamine impurities that could cause cancer.
Agency tests found the N-Nitrosodimethylamine (NDMA) nitrosamine impurity in a range of oral solid and oral liquid dosage forms from 12 manufacturers, but generally at levels below the